View ValuationBioPorto 향후 성장Future 기준 점검 6/6BioPorto (는) 각각 연간 78.7% 및 43.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 76.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 82.8% 로 예상됩니다.핵심 정보78.7%이익 성장률76.28%EPS 성장률Biotechs 이익 성장25.3%매출 성장률43.1%향후 자기자본이익률82.80%애널리스트 커버리지Low마지막 업데이트09 Apr 2026최근 향후 성장 업데이트공시 • 22hBioporto A/S Un-changes Earnings Guidance for the Full Year 2026BioPorto A/S unchanged earnings guidance for the full year 2026. For the full year 2026, Guidance for 2026 remains unchanged as announced April 8, 2026. The Company therefore expects total revenue of DKK 38 million to DKK 48 million, total NGAL revenue of DKK 33 million to DKK 42 million.공시 • Apr 10+ 1 more updateBioPorto A/S Updates Earnings Guidance for the Full Year 2026BioPorto A/S updated earnings guidance for the full year 2026. For the full year 2026, the company now expects total revenue of DKK 38 million to DKK 48 million against previous guidance of DKK 48 million to DKK 58 million. The reason for adjusting guidance is because BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC.공시 • Mar 28+ 3 more updatesBioporto A/S Reaffirmed Earnings Guidance for the Fiscal Year 2026BioPorto A/S reaffirmed earnings guidance for the fiscal year 2026. For the period, the company expects total Revenue to be in the range of DKK 48 million - DKK 58 million.공시 • Feb 06BioPorto A/S Provides Its Earnings Guidance for Full Year 2026BioPorto A/S provided its earnings guidance for full year 2026. For the year, the company For 2026, the total NGAL revenue is expected in range of DKK 48 Million to DKK 58 million.공시 • Nov 20BioPorto A/S Confirms Earnings Guidance for Full Year 2025BioPorto A/S confirmed its earnings guidance for full year 2025. For the year, the company total revenue expectation is to be in the range of DKK 40 million - DKK 45 million.공시 • Mar 20BioPorto Provides Earnings Guidance for the Fiscal Year 2025 and Aspirations for 2026 Towards 2029BioPorto A/S provided earnings guidance for the fiscal year 2025. For the year, the company is targeting total revenue of DKK 45 million to DKK 60 million, corresponding to a growth in the range of 24 % to 66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded. For the 2026, the company aspired to reach total revenue of DKK 80 million to DKK 125 million (app. USD 12 million to USD 18 million). BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029.모든 업데이트 보기Recent updates공시 • 22hBioporto A/S Un-changes Earnings Guidance for the Full Year 2026BioPorto A/S unchanged earnings guidance for the full year 2026. For the full year 2026, Guidance for 2026 remains unchanged as announced April 8, 2026. The Company therefore expects total revenue of DKK 38 million to DKK 48 million, total NGAL revenue of DKK 33 million to DKK 42 million.공시 • Apr 10+ 1 more updateBioPorto A/S Updates Earnings Guidance for the Full Year 2026BioPorto A/S updated earnings guidance for the full year 2026. For the full year 2026, the company now expects total revenue of DKK 38 million to DKK 48 million against previous guidance of DKK 48 million to DKK 58 million. The reason for adjusting guidance is because BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC.공시 • Apr 02Bioporto A/S Advances U.S. Adult Urine Ngal Program with Fda Pre-Submission RequestBioPorto A/S had formally submitted its FDA pre-submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary analysis recently completed for the U.S. adult urine NGAL Cut-off Study. On 18 March 2026, BioPorto reported that the preliminary analysis demonstrated results supporting the study’s primary endpoint, providing the foundation for the next phase of the Company’s regulatory strategy. Building on these findings, BioPorto has now submitted its FDA pre-submission package, seeking Agency feedback on the proposed clinical study design for the upcoming Validation Study, which is an essential step toward U.S. regulatory 510(k) clearance. With the pre-submission meeting package now filed, BioPorto seeks FDA feedback to align with the Agency on the Validation Study protocol. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026.공시 • Mar 28+ 3 more updatesBioporto A/S Reaffirmed Earnings Guidance for the Fiscal Year 2026BioPorto A/S reaffirmed earnings guidance for the fiscal year 2026. For the period, the company expects total Revenue to be in the range of DKK 48 million - DKK 58 million.공시 • Mar 27BioPorto A/S, Annual General Meeting, Apr 24, 2026BioPorto A/S, Annual General Meeting, Apr 24, 2026, at 15:00 Romance Standard Time. Location: tuborg havnevej 15, st., dk-2900 hellerup, Denmark공시 • Mar 20BioPorto A S Successfully Completes Preliminary Analysis of U S Adult NGAL Cutoff StudyBioPorto A/S announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of NGAL in assessing risk of acute kidney injury (AKI). The Company intends to submit its FDA Pre-submission package by the end of March 2026, to ensure robustness in its subsequent Validation Study. Patient enrollment was completed in October 2025, and database lock was finalized in March 2026. The preliminary analysis of the adult study has shown positive results supporting the study’s primary endpoint, consistent with the findings from the Company’s cutoff and validation study conducted in the pediatric segment, which subsequently led to FDA clearance at the end of 2023 for the pediatric indication. This is providing a strong foundation for BioPorto’s regulatory strategy going forward. The planned Pre-submission will seek FDA’s feedback on the regulatory pathway as well as the design of analytical and clinical study protocols for the Validation Study. Subsequently, the Validation Study will be initiated. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026.공시 • Feb 11+ 1 more updateBioPorto A/S Appoints Klaus Juhl Wulff as Chief Financial Officer, Effective May 1, 2026BioPorto A/S announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl Wulff has acted as CFO across various companies. Klaus Juhl Wulff holds a Master of Science in Finance and Administration from Aarhus University supplemented with various leadership education.공시 • Feb 06BioPorto A/S Provides Its Earnings Guidance for Full Year 2026BioPorto A/S provided its earnings guidance for full year 2026. For the year, the company For 2026, the total NGAL revenue is expected in range of DKK 48 Million to DKK 58 million.공시 • Dec 13BioPorto A/S Announces Resignation of CFO Niels Høy NielsenBioPorto A/S announced that Niels Høy Nielsen has resigned as Chief Financial Officer of BioPorto to become CFO at another company. Niels Høy Nielsen will continue to serve in his current role at the Company through March 2026.공시 • Nov 25+ 3 more updatesBioPorto A/S to Report Nine Months, 2026 Results on Nov 19, 2026BioPorto A/S announced that they will report nine months, 2026 results on Nov 19, 2026공시 • Nov 20BioPorto A/S Confirms Earnings Guidance for Full Year 2025BioPorto A/S confirmed its earnings guidance for full year 2025. For the year, the company total revenue expectation is to be in the range of DKK 40 million - DKK 45 million.공시 • Nov 14+ 1 more updateBioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 43.349993 million.BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 43.349993 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,438,426 Price\Range: DKK 1.072 Transaction Features: Subsequent Direct Listing공시 • Jun 30Bioporto A/S Announces Initiation of Commercialization of Pronephro Aki (Ngal) for Diagnostic Use in the UsBioPorto A/S announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AK ITM (NGAL) for the US market. This purchase order is to service US hospitals through BioPorto's distribution relationship with Roche Diagnostics. Currently, ProNephro AKI TM (NGAL) has FDA 510(k) marketing clearance for Roche's cobas®? c501 analyzers, that are broadly available in standard medical laboratories and hospitals.공시 • Apr 15BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million.BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: DKK 1.3402 Transaction Features: Subsequent Direct Listing공시 • Apr 14BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million.BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: DKK 1.3402 Transaction Features: Subsequent Direct Listing공시 • Apr 12BioPorto A/S Approves Board AppointmentsBioPorto A/S held its Annual General on April 11, 2025, elected Jens Due Olsen and Donna Haire as new members of the Board of Directors. After the Annual General Meeting, the Board of Directors constituted itself by electing Jens Due Olsen as Chair and Henrik Juuel as Vice Chair of the Board of Directors.공시 • Mar 20BioPorto Provides Earnings Guidance for the Fiscal Year 2025 and Aspirations for 2026 Towards 2029BioPorto A/S provided earnings guidance for the fiscal year 2025. For the year, the company is targeting total revenue of DKK 45 million to DKK 60 million, corresponding to a growth in the range of 24 % to 66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded. For the 2026, the company aspired to reach total revenue of DKK 80 million to DKK 125 million (app. USD 12 million to USD 18 million). BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029.공시 • Mar 06BioPorto A/S, Annual General Meeting, Apr 11, 2025BioPorto A/S, Annual General Meeting, Apr 11, 2025.공시 • Mar 05Bioporto A/S Announces Ninfa Saunders, Michael S. Singer and Don M. Hardison Will Not Seek Re-ElectionBioPorto A/S announced that Ninfa Saunders, Michael S. Singer and Don M. Hardison will not seek re-election at the General Meeting.공시 • Feb 28BioPorto A/S Appoints Hanne Søgaard as Head of Investor Relations, Effective 1 March 2025BioPorto A/S announced that, effective 1 March 2025, Hanne Søgaard will join BioPorto as the Company's new Head of Investor Relations. Hanne brings extensive experience within Investor Relations and financial communication, having previously led Nykredit's Investor Relations and ESG initiatives. With a strong background in financial analysis and communication from her roles at Nykredit, Juristernes og Økonomernes Pensionskasse, Danske Markets, Skandia Pension, and Alm. Brand Forsikring, Hanne is well-suited to enhance Investor Relations efforts communicating and engaging with investors on strategy and helping drive strategic goals forward.공시 • Jan 30BioPorto A/S Announces Board ChangesBioPorto A/S announced that Board Member Henrik Juuel will be appointed interim Chairman of the Board of Directors in BioPorto A/S as John McDonough steps down and resigns as Chair and member of the Board of Directors at the end of this month. Henrik Juuel joined the Board of Directors of BioPorto A/S in 2024 and has more than 30 years of experience from the Life Science industry. Henrik is EVP & CFO of Bavarian Nordic A/S since 2018. Until the Annual General Meeting on April 11, 2025, focus will be on assessing the necessary composition of the Board to address the needs of the Company during its initiation of commercialization and indication expansion phase. As announced on December 16, 2024, the Board is seeking a new Chair to be elected at the Company’s Annual General Meeting in April 2025, which can support the Company’s engagement with investors and stakeholders in the local market and contribute to the Company’s growth.공시 • Jan 23BioPorto A/S Announces the Publication of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL)Reference Intervals in Healthy Adult and Pediatric IndividualsBioPorto A/S announced their publication of reference intervals using BioPorto's NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients. The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required step for laboratories to implement clinical tests. These findings address the critical gaps in kidney injury management and ultimately can help with earlier identification of AKI with the use of biomarkers. This BioPorto study is the largest comprehensive study to date of 629 patients with ages ranging from three months to older than 65 years.공시 • Dec 17+ 4 more updatesBioPorto A/S to Report Q3, 2025 Results on Nov 19, 2025BioPorto A/S announced that they will report Q3, 2025 results on Nov 19, 2025공시 • Nov 14Bioporto A/S Maintains Revenue Guidance for the Year 2024BioPorto A/S maintained revenue guidance for the year 2024. Based on the progress and results obtained in the first nine months of 2024 the company maintains Total Revenue target of DKK 40 million.공시 • Oct 29BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General HospitalBioPorto A/S announced the enrollment of the first patient in its US clinical study for ProNephro AKI (NGAL) with the goal of determining a cut-off point for risk stratification of moderate to severe of AKI in adult patients. BioPorto's ProNephro AKI (NGAL), currently cleared by the US Food and Drug Administration (FDA) for those 3 months through 21 years of age, has been widely recognized for its groundbreaking potential in refining AKI diagnosis. NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than previously possible. Early detection of AKI may enable prompt intervention to save lives. BioPorto's proprietary assay is a kidney injury marker versus the traditionally used serum creatinine (SCr) functional test. The cut-off study is the first of two studies which will form a substantial part of the submission for US clearance of ProNephro AKI (NGAL) in adult patients. The cut-off study seeks to enroll patients at up to 12 US sites in 2024 and 2025. After having established the cut-off, BioPorto expects to commence enrollment for the second study, the validation study, enabling the Company to submit its FDA application for adult usage of ProNephro AKI (NGAL) by 2026.공시 • Aug 15Bioporto A/S Affirms Earnings Guidance for 2024BioPorto A/S affirmed earnings guidance for 2024. For the period, the company expects total revenue target of DKK 40 million.공시 • May 31+ 1 more updateBioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024BioPorto A/S announced the appointment of Niels Høy Nielsen as its new Executive Vice President (EVP) and member of the Executive Management team as of August 1, 2024. Niels Høy Nielsen is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from ChemoMetec A/S, a Danish NASDAQ listed healthcare company, where he served as CFO from 2022. Prior to this, Niels Høy Nielsen was the CFO of ConvaTec, Infusion Care, a global distributor of medtech products within wound and stoma care, and before that a 10-year tenure with LEO Pharma A/S, heading up departments in finance, commercial and manufacturing. Niels Høy Nielsen holds a Master of Science in Finance and Accounting from Aarhus School of Business supplemented with leadership education at IMD. With this hiring, BioPorto has now established its new leadership team with Peter Mørch Eriksen as Group CEO, Gry Husby Larsen as EVP & CLO, Niels Høy Nielsen as EVP & CFO and Jeffrey Haas as President & CEO of BioPorto’s subsidiary BioPorto Inc.공시 • May 09Bioporto A/S Provides Revenue Guidance for 2024BioPorto A/S provided revenue guidance for 2024. For the period, the company expects total revenue target of DKK 40 million.공시 • Apr 10Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024BioPorto A/S announced the appointment of Gry Louise Husby Larsen as its new Executive Vice President and Chief Legal Officer (CLO), and member of the Executive Management team as of April 15, 2024. Gry Louise Husby Larsen has been employed as General Counsel at BioPorto from 2011 leading the Company’s corporate legal activities within compliance, fundraising, IPR, contracts, HR and ESG ect. In the period from 2019 to 2024, Gry Louise Husby Larsen acted as external General Counsel for BioPorto while also serving as part time General Counsel for FluoGuide A/S, Algiecel A/S and Unibio A/S. Gry Louise Husby Larsen holds a Master of Law from University of Copenhagen and was an Attorney-at-law at Knop & Co. Law Firm until 2011. To further strengthen the leadership of BioPorto, the company expects to announce the appointment of a US CEO for BioPorto’s subsidiary BioPorto Inc. and a group CFO later this quarter.공시 • Apr 05Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for ElectionBioPorto A/S announced that it has received notice that Tonni Bülow-Nielsen, due to personal reasons, will not be a candidate for the upcoming general meeting on 30 April 2024.공시 • Jan 10BioPorto A/S Announces CEO ChangesBioPorto A/S announced changes to the Executive Management. By mutual agreement, BioPorto’s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from January 9, 2024. Peter Mørch Eriksen has been appointed as interim CEO. The Board of Directors has as of January 9, 2024 appointed Board Member Peter Mørch Eriksen as interim CEO of the Company. Peter Mørch Eriksen will remain in his position as Board Member at least until the expiry of his election period at this year’s Annual General Meeting. Peter Mørch Eriksen has spent more than 25 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic. Peter has previously been the CEO of BioPorto in the period from 2013 – 2021 and has served as a Board Member in BioPorto since then. Further, Peter is the Chairman of FluoGuide A/S and MONSENSO A/S. Together with the Board of Directors and the BioPorto team, Peter will finalize work that has already been commenced on the Company’s plans for commercialization, FDA instrument- & indication expansion, financial guidance for 2024 and capital requirements which is to be published by mid-February 2024.공시 • Dec 17+ 3 more updatesBioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024BioPorto A/S announced that they will report nine months, 2024 results on Oct 30, 2024공시 • Dec 16BioPorto A/S, Annual General Meeting, Apr 30, 2024BioPorto A/S, Annual General Meeting, Apr 30, 2024.공시 • Dec 08BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United StatesBioPorto A/S announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be marketed as ProNephro AKITM (NGAL). ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker test cleared for pediatric use (aged 3 months through 21 years) in the US. ProNephro AKI (NGAL) is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI within 48-72 hours in the intensive care unit (ICU) setting. Unlike serum creatinine, a muscle by-product that is the current standard of care but slow to rise in AKI, NGAL is a direct real time marker of kidney cell damage and can potentially detect AKI days earlier than serum creatinine. Early detection of AKI may enable prompt intervention to save lives. Until now, the risk for developing or having persistent AKI has been difficult to assess early because current standard-of-care methods, such as sCr, rise slowly in AKI. As such, ProNephro AKI (NGAL) was developed to help save kidneys and lives through faster and more timely intervention.공시 • Dec 05BioPorto A/S Announces Resignation of Jan Leth Christensen as Board MemberBioPorto A/S announced that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024.공시 • Nov 01Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023BioPorto A/S provided revenue guidance for the fiscal year 2023, for the year, the company expects revenue of approximately DKK 30 million to DKK 33 million.공시 • Sep 20Bioporto A/S Announces Resignation of Neil Goldman as CFOBioPorto A/S announced that Neil Goldman has informed the Company that he has decided to resign to take up the CFO position at another company. The search for a successor will be initiated and Neil Goldman will assist with the transition until a date to be determined.공시 • Aug 02BioPorto A/S announced that it has received $0.11 million in fundingOn July 31, 2023, BioPorto A/S closed the transaction. The transaction included participation from 8 investor.공시 • Aug 01BioPorto A/S Maintains Earnings Guidance for the Year 2023BioPorto A/S maintained earnings guidance for the year 2023. Based on the progress and results obtained in the first six months of 2023, the company maintains its financial guidance for 2023. Revenue of approximately DKK 30 million to DKK 33 million.공시 • May 11BioPorto A/S Maintains Financial Guidance for 2023BioPorto A/S maintained financial guidance for 2023. Based on the progress and results obtained in the first three months of 2023, BioPorto maintains its financial guidance for 2023, as most recently described in its Annual Report 2022 of: Revenue of approximately DKK 30 million to DKK 33 million.공시 • Dec 31+ 1 more updateBioPorto A/S to Report First Half, 2023 Results on Aug 01, 2023BioPorto A/S announced that they will report first half, 2023 results on Aug 01, 2023이익 및 매출 성장 예측OTCPK:THOX.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (DKK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202814325-95112/31/202760-34-51-43112/31/202642-10-18-13112/31/202540-82-77-77N/A9/30/202537-87-81-80N/A6/30/202536-84-87-85N/A3/31/202534-82-89-87N/A12/31/202436-68-84-84N/A9/30/202435-61-68-68N/A6/30/202434-50-56-56N/A3/31/202432-54-50-50N/A12/31/202331-56-55-55N/A9/30/202333-70-69-69N/A6/30/202330-78-63-63N/A3/31/202331-75-62-62N/A12/31/202229-76-53-52N/A9/30/202227-68-51-51N/A6/30/202227-62-59-58N/A3/31/202225-59-61-60N/A12/31/202124-57-65-65N/A9/30/202125-54-59-58N/A6/30/202124-60-48-47N/A3/31/202125-62-44-43N/A12/31/202023-62-37-36N/A9/30/202022-64-43-42N/A6/30/202024-68-55-55N/A3/31/202025-69-62-61N/A12/31/201927-70-61-60N/A9/30/201929-61N/A-51N/A6/30/201928-51N/A-44N/A3/31/201927-43N/A-39N/A12/31/201826-38N/A-38N/A9/30/201824-38N/A-39N/A6/30/201825-36N/A-38N/A3/31/201824-35N/A-36N/A12/31/201725-32N/A-29N/A9/30/201725-29N/A-26N/A6/30/201723-27N/A-25N/A3/31/201721-26N/A-21N/A12/31/201621-23N/A-20N/A9/30/201620-21N/A-21N/A6/30/201620-16N/A-20N/A3/31/201621-12N/A-18N/A12/31/201520-11N/A-17N/A9/30/201520-11N/A-15N/A6/30/201519-12N/A-14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: THOX.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: THOX.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: THOX.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: THOX.F 의 수익(연간 43.1%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: THOX.F 의 수익(연간 43.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: THOX.F의 자본 수익률은 3년 후 82.8%로 매우 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/28 19:29종가2026/01/29 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioPorto A/S는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullBrookline Capital MarketsNiels Granholm-LethDNB Carnegie Commissioned ResearchJyoti PrakashEdison Investment Research
공시 • 22hBioporto A/S Un-changes Earnings Guidance for the Full Year 2026BioPorto A/S unchanged earnings guidance for the full year 2026. For the full year 2026, Guidance for 2026 remains unchanged as announced April 8, 2026. The Company therefore expects total revenue of DKK 38 million to DKK 48 million, total NGAL revenue of DKK 33 million to DKK 42 million.
공시 • Apr 10+ 1 more updateBioPorto A/S Updates Earnings Guidance for the Full Year 2026BioPorto A/S updated earnings guidance for the full year 2026. For the full year 2026, the company now expects total revenue of DKK 38 million to DKK 48 million against previous guidance of DKK 48 million to DKK 58 million. The reason for adjusting guidance is because BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC.
공시 • Mar 28+ 3 more updatesBioporto A/S Reaffirmed Earnings Guidance for the Fiscal Year 2026BioPorto A/S reaffirmed earnings guidance for the fiscal year 2026. For the period, the company expects total Revenue to be in the range of DKK 48 million - DKK 58 million.
공시 • Feb 06BioPorto A/S Provides Its Earnings Guidance for Full Year 2026BioPorto A/S provided its earnings guidance for full year 2026. For the year, the company For 2026, the total NGAL revenue is expected in range of DKK 48 Million to DKK 58 million.
공시 • Nov 20BioPorto A/S Confirms Earnings Guidance for Full Year 2025BioPorto A/S confirmed its earnings guidance for full year 2025. For the year, the company total revenue expectation is to be in the range of DKK 40 million - DKK 45 million.
공시 • Mar 20BioPorto Provides Earnings Guidance for the Fiscal Year 2025 and Aspirations for 2026 Towards 2029BioPorto A/S provided earnings guidance for the fiscal year 2025. For the year, the company is targeting total revenue of DKK 45 million to DKK 60 million, corresponding to a growth in the range of 24 % to 66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded. For the 2026, the company aspired to reach total revenue of DKK 80 million to DKK 125 million (app. USD 12 million to USD 18 million). BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029.
공시 • 22hBioporto A/S Un-changes Earnings Guidance for the Full Year 2026BioPorto A/S unchanged earnings guidance for the full year 2026. For the full year 2026, Guidance for 2026 remains unchanged as announced April 8, 2026. The Company therefore expects total revenue of DKK 38 million to DKK 48 million, total NGAL revenue of DKK 33 million to DKK 42 million.
공시 • Apr 10+ 1 more updateBioPorto A/S Updates Earnings Guidance for the Full Year 2026BioPorto A/S updated earnings guidance for the full year 2026. For the full year 2026, the company now expects total revenue of DKK 38 million to DKK 48 million against previous guidance of DKK 48 million to DKK 58 million. The reason for adjusting guidance is because BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC.
공시 • Apr 02Bioporto A/S Advances U.S. Adult Urine Ngal Program with Fda Pre-Submission RequestBioPorto A/S had formally submitted its FDA pre-submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary analysis recently completed for the U.S. adult urine NGAL Cut-off Study. On 18 March 2026, BioPorto reported that the preliminary analysis demonstrated results supporting the study’s primary endpoint, providing the foundation for the next phase of the Company’s regulatory strategy. Building on these findings, BioPorto has now submitted its FDA pre-submission package, seeking Agency feedback on the proposed clinical study design for the upcoming Validation Study, which is an essential step toward U.S. regulatory 510(k) clearance. With the pre-submission meeting package now filed, BioPorto seeks FDA feedback to align with the Agency on the Validation Study protocol. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026.
공시 • Mar 28+ 3 more updatesBioporto A/S Reaffirmed Earnings Guidance for the Fiscal Year 2026BioPorto A/S reaffirmed earnings guidance for the fiscal year 2026. For the period, the company expects total Revenue to be in the range of DKK 48 million - DKK 58 million.
공시 • Mar 27BioPorto A/S, Annual General Meeting, Apr 24, 2026BioPorto A/S, Annual General Meeting, Apr 24, 2026, at 15:00 Romance Standard Time. Location: tuborg havnevej 15, st., dk-2900 hellerup, Denmark
공시 • Mar 20BioPorto A S Successfully Completes Preliminary Analysis of U S Adult NGAL Cutoff StudyBioPorto A/S announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff Study, designed to evaluate the clinical performance of NGAL in assessing risk of acute kidney injury (AKI). The Company intends to submit its FDA Pre-submission package by the end of March 2026, to ensure robustness in its subsequent Validation Study. Patient enrollment was completed in October 2025, and database lock was finalized in March 2026. The preliminary analysis of the adult study has shown positive results supporting the study’s primary endpoint, consistent with the findings from the Company’s cutoff and validation study conducted in the pediatric segment, which subsequently led to FDA clearance at the end of 2023 for the pediatric indication. This is providing a strong foundation for BioPorto’s regulatory strategy going forward. The planned Pre-submission will seek FDA’s feedback on the regulatory pathway as well as the design of analytical and clinical study protocols for the Validation Study. Subsequently, the Validation Study will be initiated. This announcement does not alter BioPorto’s financial guidance as recently published on 5 February 2026.
공시 • Feb 11+ 1 more updateBioPorto A/S Appoints Klaus Juhl Wulff as Chief Financial Officer, Effective May 1, 2026BioPorto A/S announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl Wulff has acted as CFO across various companies. Klaus Juhl Wulff holds a Master of Science in Finance and Administration from Aarhus University supplemented with various leadership education.
공시 • Feb 06BioPorto A/S Provides Its Earnings Guidance for Full Year 2026BioPorto A/S provided its earnings guidance for full year 2026. For the year, the company For 2026, the total NGAL revenue is expected in range of DKK 48 Million to DKK 58 million.
공시 • Dec 13BioPorto A/S Announces Resignation of CFO Niels Høy NielsenBioPorto A/S announced that Niels Høy Nielsen has resigned as Chief Financial Officer of BioPorto to become CFO at another company. Niels Høy Nielsen will continue to serve in his current role at the Company through March 2026.
공시 • Nov 25+ 3 more updatesBioPorto A/S to Report Nine Months, 2026 Results on Nov 19, 2026BioPorto A/S announced that they will report nine months, 2026 results on Nov 19, 2026
공시 • Nov 20BioPorto A/S Confirms Earnings Guidance for Full Year 2025BioPorto A/S confirmed its earnings guidance for full year 2025. For the year, the company total revenue expectation is to be in the range of DKK 40 million - DKK 45 million.
공시 • Nov 14+ 1 more updateBioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 43.349993 million.BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 43.349993 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,438,426 Price\Range: DKK 1.072 Transaction Features: Subsequent Direct Listing
공시 • Jun 30Bioporto A/S Announces Initiation of Commercialization of Pronephro Aki (Ngal) for Diagnostic Use in the UsBioPorto A/S announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AK ITM (NGAL) for the US market. This purchase order is to service US hospitals through BioPorto's distribution relationship with Roche Diagnostics. Currently, ProNephro AKI TM (NGAL) has FDA 510(k) marketing clearance for Roche's cobas®? c501 analyzers, that are broadly available in standard medical laboratories and hospitals.
공시 • Apr 15BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million.BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 33.505 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: DKK 1.3402 Transaction Features: Subsequent Direct Listing
공시 • Apr 14BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million.BioPorto A/S has filed a Follow-on Equity Offering in the amount of DKK 33.505 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: DKK 1.3402 Transaction Features: Subsequent Direct Listing
공시 • Apr 12BioPorto A/S Approves Board AppointmentsBioPorto A/S held its Annual General on April 11, 2025, elected Jens Due Olsen and Donna Haire as new members of the Board of Directors. After the Annual General Meeting, the Board of Directors constituted itself by electing Jens Due Olsen as Chair and Henrik Juuel as Vice Chair of the Board of Directors.
공시 • Mar 20BioPorto Provides Earnings Guidance for the Fiscal Year 2025 and Aspirations for 2026 Towards 2029BioPorto A/S provided earnings guidance for the fiscal year 2025. For the year, the company is targeting total revenue of DKK 45 million to DKK 60 million, corresponding to a growth in the range of 24 % to 66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded. For the 2026, the company aspired to reach total revenue of DKK 80 million to DKK 125 million (app. USD 12 million to USD 18 million). BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029.
공시 • Mar 06BioPorto A/S, Annual General Meeting, Apr 11, 2025BioPorto A/S, Annual General Meeting, Apr 11, 2025.
공시 • Mar 05Bioporto A/S Announces Ninfa Saunders, Michael S. Singer and Don M. Hardison Will Not Seek Re-ElectionBioPorto A/S announced that Ninfa Saunders, Michael S. Singer and Don M. Hardison will not seek re-election at the General Meeting.
공시 • Feb 28BioPorto A/S Appoints Hanne Søgaard as Head of Investor Relations, Effective 1 March 2025BioPorto A/S announced that, effective 1 March 2025, Hanne Søgaard will join BioPorto as the Company's new Head of Investor Relations. Hanne brings extensive experience within Investor Relations and financial communication, having previously led Nykredit's Investor Relations and ESG initiatives. With a strong background in financial analysis and communication from her roles at Nykredit, Juristernes og Økonomernes Pensionskasse, Danske Markets, Skandia Pension, and Alm. Brand Forsikring, Hanne is well-suited to enhance Investor Relations efforts communicating and engaging with investors on strategy and helping drive strategic goals forward.
공시 • Jan 30BioPorto A/S Announces Board ChangesBioPorto A/S announced that Board Member Henrik Juuel will be appointed interim Chairman of the Board of Directors in BioPorto A/S as John McDonough steps down and resigns as Chair and member of the Board of Directors at the end of this month. Henrik Juuel joined the Board of Directors of BioPorto A/S in 2024 and has more than 30 years of experience from the Life Science industry. Henrik is EVP & CFO of Bavarian Nordic A/S since 2018. Until the Annual General Meeting on April 11, 2025, focus will be on assessing the necessary composition of the Board to address the needs of the Company during its initiation of commercialization and indication expansion phase. As announced on December 16, 2024, the Board is seeking a new Chair to be elected at the Company’s Annual General Meeting in April 2025, which can support the Company’s engagement with investors and stakeholders in the local market and contribute to the Company’s growth.
공시 • Jan 23BioPorto A/S Announces the Publication of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL)Reference Intervals in Healthy Adult and Pediatric IndividualsBioPorto A/S announced their publication of reference intervals using BioPorto's NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients. The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required step for laboratories to implement clinical tests. These findings address the critical gaps in kidney injury management and ultimately can help with earlier identification of AKI with the use of biomarkers. This BioPorto study is the largest comprehensive study to date of 629 patients with ages ranging from three months to older than 65 years.
공시 • Dec 17+ 4 more updatesBioPorto A/S to Report Q3, 2025 Results on Nov 19, 2025BioPorto A/S announced that they will report Q3, 2025 results on Nov 19, 2025
공시 • Nov 14Bioporto A/S Maintains Revenue Guidance for the Year 2024BioPorto A/S maintained revenue guidance for the year 2024. Based on the progress and results obtained in the first nine months of 2024 the company maintains Total Revenue target of DKK 40 million.
공시 • Oct 29BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General HospitalBioPorto A/S announced the enrollment of the first patient in its US clinical study for ProNephro AKI (NGAL) with the goal of determining a cut-off point for risk stratification of moderate to severe of AKI in adult patients. BioPorto's ProNephro AKI (NGAL), currently cleared by the US Food and Drug Administration (FDA) for those 3 months through 21 years of age, has been widely recognized for its groundbreaking potential in refining AKI diagnosis. NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than previously possible. Early detection of AKI may enable prompt intervention to save lives. BioPorto's proprietary assay is a kidney injury marker versus the traditionally used serum creatinine (SCr) functional test. The cut-off study is the first of two studies which will form a substantial part of the submission for US clearance of ProNephro AKI (NGAL) in adult patients. The cut-off study seeks to enroll patients at up to 12 US sites in 2024 and 2025. After having established the cut-off, BioPorto expects to commence enrollment for the second study, the validation study, enabling the Company to submit its FDA application for adult usage of ProNephro AKI (NGAL) by 2026.
공시 • Aug 15Bioporto A/S Affirms Earnings Guidance for 2024BioPorto A/S affirmed earnings guidance for 2024. For the period, the company expects total revenue target of DKK 40 million.
공시 • May 31+ 1 more updateBioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024BioPorto A/S announced the appointment of Niels Høy Nielsen as its new Executive Vice President (EVP) and member of the Executive Management team as of August 1, 2024. Niels Høy Nielsen is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from ChemoMetec A/S, a Danish NASDAQ listed healthcare company, where he served as CFO from 2022. Prior to this, Niels Høy Nielsen was the CFO of ConvaTec, Infusion Care, a global distributor of medtech products within wound and stoma care, and before that a 10-year tenure with LEO Pharma A/S, heading up departments in finance, commercial and manufacturing. Niels Høy Nielsen holds a Master of Science in Finance and Accounting from Aarhus School of Business supplemented with leadership education at IMD. With this hiring, BioPorto has now established its new leadership team with Peter Mørch Eriksen as Group CEO, Gry Husby Larsen as EVP & CLO, Niels Høy Nielsen as EVP & CFO and Jeffrey Haas as President & CEO of BioPorto’s subsidiary BioPorto Inc.
공시 • May 09Bioporto A/S Provides Revenue Guidance for 2024BioPorto A/S provided revenue guidance for 2024. For the period, the company expects total revenue target of DKK 40 million.
공시 • Apr 10Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024BioPorto A/S announced the appointment of Gry Louise Husby Larsen as its new Executive Vice President and Chief Legal Officer (CLO), and member of the Executive Management team as of April 15, 2024. Gry Louise Husby Larsen has been employed as General Counsel at BioPorto from 2011 leading the Company’s corporate legal activities within compliance, fundraising, IPR, contracts, HR and ESG ect. In the period from 2019 to 2024, Gry Louise Husby Larsen acted as external General Counsel for BioPorto while also serving as part time General Counsel for FluoGuide A/S, Algiecel A/S and Unibio A/S. Gry Louise Husby Larsen holds a Master of Law from University of Copenhagen and was an Attorney-at-law at Knop & Co. Law Firm until 2011. To further strengthen the leadership of BioPorto, the company expects to announce the appointment of a US CEO for BioPorto’s subsidiary BioPorto Inc. and a group CFO later this quarter.
공시 • Apr 05Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for ElectionBioPorto A/S announced that it has received notice that Tonni Bülow-Nielsen, due to personal reasons, will not be a candidate for the upcoming general meeting on 30 April 2024.
공시 • Jan 10BioPorto A/S Announces CEO ChangesBioPorto A/S announced changes to the Executive Management. By mutual agreement, BioPorto’s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from January 9, 2024. Peter Mørch Eriksen has been appointed as interim CEO. The Board of Directors has as of January 9, 2024 appointed Board Member Peter Mørch Eriksen as interim CEO of the Company. Peter Mørch Eriksen will remain in his position as Board Member at least until the expiry of his election period at this year’s Annual General Meeting. Peter Mørch Eriksen has spent more than 25 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic. Peter has previously been the CEO of BioPorto in the period from 2013 – 2021 and has served as a Board Member in BioPorto since then. Further, Peter is the Chairman of FluoGuide A/S and MONSENSO A/S. Together with the Board of Directors and the BioPorto team, Peter will finalize work that has already been commenced on the Company’s plans for commercialization, FDA instrument- & indication expansion, financial guidance for 2024 and capital requirements which is to be published by mid-February 2024.
공시 • Dec 17+ 3 more updatesBioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024BioPorto A/S announced that they will report nine months, 2024 results on Oct 30, 2024
공시 • Dec 16BioPorto A/S, Annual General Meeting, Apr 30, 2024BioPorto A/S, Annual General Meeting, Apr 30, 2024.
공시 • Dec 08BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United StatesBioPorto A/S announced receipt of a US Food and Drug Administration (FDA) 510(k) clearance for BioPorto’s NGAL test, to be marketed as ProNephro AKITM (NGAL). ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker test cleared for pediatric use (aged 3 months through 21 years) in the US. ProNephro AKI (NGAL) is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI within 48-72 hours in the intensive care unit (ICU) setting. Unlike serum creatinine, a muscle by-product that is the current standard of care but slow to rise in AKI, NGAL is a direct real time marker of kidney cell damage and can potentially detect AKI days earlier than serum creatinine. Early detection of AKI may enable prompt intervention to save lives. Until now, the risk for developing or having persistent AKI has been difficult to assess early because current standard-of-care methods, such as sCr, rise slowly in AKI. As such, ProNephro AKI (NGAL) was developed to help save kidneys and lives through faster and more timely intervention.
공시 • Dec 05BioPorto A/S Announces Resignation of Jan Leth Christensen as Board MemberBioPorto A/S announced that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024.
공시 • Nov 01Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023BioPorto A/S provided revenue guidance for the fiscal year 2023, for the year, the company expects revenue of approximately DKK 30 million to DKK 33 million.
공시 • Sep 20Bioporto A/S Announces Resignation of Neil Goldman as CFOBioPorto A/S announced that Neil Goldman has informed the Company that he has decided to resign to take up the CFO position at another company. The search for a successor will be initiated and Neil Goldman will assist with the transition until a date to be determined.
공시 • Aug 02BioPorto A/S announced that it has received $0.11 million in fundingOn July 31, 2023, BioPorto A/S closed the transaction. The transaction included participation from 8 investor.
공시 • Aug 01BioPorto A/S Maintains Earnings Guidance for the Year 2023BioPorto A/S maintained earnings guidance for the year 2023. Based on the progress and results obtained in the first six months of 2023, the company maintains its financial guidance for 2023. Revenue of approximately DKK 30 million to DKK 33 million.
공시 • May 11BioPorto A/S Maintains Financial Guidance for 2023BioPorto A/S maintained financial guidance for 2023. Based on the progress and results obtained in the first three months of 2023, BioPorto maintains its financial guidance for 2023, as most recently described in its Annual Report 2022 of: Revenue of approximately DKK 30 million to DKK 33 million.
공시 • Dec 31+ 1 more updateBioPorto A/S to Report First Half, 2023 Results on Aug 01, 2023BioPorto A/S announced that they will report first half, 2023 results on Aug 01, 2023